`No.
`2141
`2142
`2143
`
`2144
`
`2145
`
`2146
`
`2147
`
`2148
`
`2149
`
`Patent Owner’s Proposed Supplemental Exhibits
`
`
`
`Description
`
`Analyst Report: “Spec Pharmaceuticals,” Morgan Stanley, March 3, 2014
`U.S. Patent No. 8,377,885
`Copaxone® 40 mg/mL Promotional Material: produced in In Re Copaxone
`Consolidated Cases as TEVCOP00449084–115
`Teva Internal Document: 2015 MS Mid-Year Tracker, FINAL REPORT
`APPENDIX – SEPTEMBER 2015
`Copaxone® 40 mg/mL Promotional Material: produced in In Re Copaxone
`Consolidated Cases as TEVCOP00450191–93
`Copaxone® 40 mg/mL Promotional Material: produced in In Re Copaxone
`Consolidated Cases as TEVCOP00451650–52
`Analyst Report: “Global Biotechnology and Pharmaceuticals – AAN 2014,”
`Credit Suisse, April 30, 2014.
`Analyst Report: “Multiple Sclerosis: It’s a Revolution! (vs. Evolution),”
`Credit Suisse, December 12, 2013.
`IMS Data (MS Mkt NSP Sales Ext Units- Sept 2009- Aug 2015; IMS NPA
`MD_MS SoB Weekly Split_Data Week 10-09-2015; IPS_Total
`Promotional Spend_2009-2015; NPA MS Mkt – TRx NRx DACON Oct
`2009 – Sept 2015)
`
`
`
`YEDA EXHIBIT NO. 2139
`MYLAN PHARM. v YEDA
`IPR2015-00644